Adjuvant therapy for colorectal carcinoma.

Area of Science:

• Oncology
• Surgical Oncology
• Gastrointestinal Oncology

Background:

• Colorectal adenocarcinoma is a prevalent malignancy in industrialized nations, posing a significant mortality risk.
• Despite advancements in surgical techniques, approximately 50% of patients with colorectal carcinoma succumb to the disease.
• Recent progress includes reduced surgical complications and postoperative mortality rates.

Purpose of the Study:

• To review the current status of colorectal adenocarcinoma treatment.
• To highlight the potential benefits of multimodality treatment approaches.
• To emphasize the importance of clinical trials for novel therapeutic strategies.

Main Methods:

• Review of recent studies and clinical data on colorectal adenocarcinoma.
• Analysis of the impact of radiotherapy and chemotherapy on patient outcomes.
• Discussion of the integration of multimodality treatment concepts.

Main Results:

• Radiotherapy for rectal carcinoma and 5-Fluorouracil chemotherapy with levamisole for colon carcinoma can improve results in specific subgroups.
• Multimodality treatment requires specialized equipment and expertise.
• Controlled clinical trials are recommended for implementing these advanced treatment concepts.

Conclusions:

• While surgical interventions are standard, adjuvant therapies are crucial for specific colorectal cancer patient subgroups.
• The implementation of multimodality treatment necessitates careful consideration of resources and expertise.
• Further research within controlled clinical trials is essential to optimize treatment strategies and improve survival rates for colorectal adenocarcinoma.